COCP-Novel Antiviral Drug Shows Promise Treating Norovirus
Dec 20, 2023 20:20:17 GMT
miamianne67, icemandios, and 3 more like this
Post by c2crusher on Dec 20, 2023 20:20:17 GMT
Novel Antiviral Drug Shows Promise Treating Norovirus with Dr. Sam Lee Cocrystal Pharma
empoweredpatientradio.com/novel-antiviral-drug-shows-promise-treating-norovirus-with-dr-sam-lee-cocrystal-pharma-transcript
empoweredpatientradio.com/novel-antiviral-drug-shows-promise-treating-norovirus-with-dr-sam-lee-cocrystal-pharma
COCP Cocrystal Pharma is an AI biotech.
Dr. Sam Lee:
No, the way I guess that we approach, again, I think the people have used the
artificial intelligence, that drug discovery, I think we don't use that terminology
heavily. However, our core drug development platform technologies try to
understand the viral enzymes. And that is a good starting point for developing
broad-spectrum compounds.
COVID-19 molecule CDI-988
"Is nothing like approved drugs such as Pfizer, coronavirus protease inhibitors, and Shionogi protease inhibitors.
Those compounds do not have any activity against norovirus."
Dr. Sam Lee:
But we had a pretty good prediction that norovirus would be actually a good
target, that our coronavirus inhibitors should innovate the norovirus protease.
That's how we started. Then, from there, we quickly applied our platform
approach and demonstrated that, in fact, our coronavirus protease inhibitors for
COVID treatment actually work well against the norovirus. I just want to point
out that we also evaluated the approved drugs such as Pfizer, coronavirus
protease inhibitors, and Shionogi protease inhibitors. Those compounds do not
have any activity against norovirus. This is where we could differentiate
compounds from existing protease inhibitors. So we're very excited about this.
empoweredpatientradio.com/novel-antiviral-drug-shows-promise-treating-norovirus-with-dr-sam-lee-cocrystal-pharma-transcript
empoweredpatientradio.com/novel-antiviral-drug-shows-promise-treating-norovirus-with-dr-sam-lee-cocrystal-pharma
COCP Cocrystal Pharma is an AI biotech.
Dr. Sam Lee:
No, the way I guess that we approach, again, I think the people have used the
artificial intelligence, that drug discovery, I think we don't use that terminology
heavily. However, our core drug development platform technologies try to
understand the viral enzymes. And that is a good starting point for developing
broad-spectrum compounds.
COVID-19 molecule CDI-988
"Is nothing like approved drugs such as Pfizer, coronavirus protease inhibitors, and Shionogi protease inhibitors.
Those compounds do not have any activity against norovirus."
Dr. Sam Lee:
But we had a pretty good prediction that norovirus would be actually a good
target, that our coronavirus inhibitors should innovate the norovirus protease.
That's how we started. Then, from there, we quickly applied our platform
approach and demonstrated that, in fact, our coronavirus protease inhibitors for
COVID treatment actually work well against the norovirus. I just want to point
out that we also evaluated the approved drugs such as Pfizer, coronavirus
protease inhibitors, and Shionogi protease inhibitors. Those compounds do not
have any activity against norovirus. This is where we could differentiate
compounds from existing protease inhibitors. So we're very excited about this.
